KRNY:NASDAQKearny Financial Analysis
Data as of 2026-06-21 - not real-time
$8.47
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
KRNY is trading around $8.47, comfortably above its 20‑day SMA and near its 50‑day SMA, indicating short‑term strength. The 20‑day SMA sits just above the 200‑day SMA, confirming a bullish alignment. RSI sits in the mid‑50s, suggesting no overbought pressure. MACD line has just crossed above its signal line, delivering a bullish histogram. Volume has been rising, supporting the price advance.
Fundamentals show 17.5% revenue growth year‑over‑year while operating margins exceed 30%, delivering solid profitability. The trailing P/E of ~15 is below the industry average of ~17, and the price‑to‑book under 1.0 signals an undervalued valuation. A dividend yield above 5% is attractive, yet a payout ratio near 77% and a debt load exceeding $1 billion raise sustainability questions. The stock’s beta of ~0.68 points to lower market volatility, but the regional‑bank sector carries heightened regulatory and credit‑risk exposure. Overall, the technical picture is bullish, the valuation appears undervalued, but balance‑sheet weakness tempers enthusiasm.
Fundamentals show 17.5% revenue growth year‑over‑year while operating margins exceed 30%, delivering solid profitability. The trailing P/E of ~15 is below the industry average of ~17, and the price‑to‑book under 1.0 signals an undervalued valuation. A dividend yield above 5% is attractive, yet a payout ratio near 77% and a debt load exceeding $1 billion raise sustainability questions. The stock’s beta of ~0.68 points to lower market volatility, but the regional‑bank sector carries heightened regulatory and credit‑risk exposure. Overall, the technical picture is bullish, the valuation appears undervalued, but balance‑sheet weakness tempers enthusiasm.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD crossover
- RSI in neutral range
- Price above key support level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued relative to peers
- Strong revenue growth
- Attractive dividend yield
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High debt load and dividend sustainability risk
- Low beta indicating lower volatility
- Sector exposure to regulatory and credit cycles
Key Metrics & Analysis
Financial Health
Revenue Growth17.50%
Profit Margin21.02%
P/E Ratio14.9
ROE4.75%
ROA0.47%
P/B Ratio0.7
Op. Cash Flow$31.8M
Industry P/E16.9
Technical Analysis
TrendBullish
RSI55.1
Support$7.98
Resistance$8.89
MA 20$8.36
MA 50$8.16
MA 200$7.45
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46
Valuation
Target Price$9.00
Upside/Downside6.26%
GradeUndervalued
TypeBlend
Dividend Yield5.19%
Risk Assessment
Beta0.68
Volatility24.92%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.